2022年3月21日简报:专家呼吁加快推进老年人接种疫苗;全球死亡人数降至2020.8以来很低;2021年至今4例新冠本土死亡病例,均有严重基础性疾病;

2022-03-21 MedSci整理 MedSci整理

截至北京时间2022年3月21日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过4亿7078万例,新增1,112,208例,达到470,784

截至北京时间2022年3月21日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过4亿7078万例,新增1,112,208例,达到470,784,313例。累计死亡病例610.0万例,达到6,100,472例。新增死亡为2,819例。康复为406,915,536例,重症和危重症病人达到62,252例;全球新冠确诊病例超过100万例的国家和地区达56个,125个国家和地区病例超10万例。昨日报道:2022年3月20日简报:本土疫情中轻型病例和无症状感染者占比超过95%;BA.2占全球整体病例超过75%,可能引发新的一波疫情;中国一年多来首次报告新冠死亡病例,系严重基础疾病患者

目前国内主要聚焦社会面清零。从传染病的防控就是三个原则:一是发现和管理传染源。我们搞的检测以及隔离就是为了这个。二是阻断传播途径。戴口罩、保持社交距离,包括隔离,也是为了阻断传播途径。三是保护易感人群。主要是着重于第一点,事实上,保护易感人群同样十分重要,要针对老年人,有严重基础疾病的人群接种疫苗。

事实上,此前国内接种疫苗时,对这部分人群很多地方是不予接种,或不符合接种标准。事实上,这部分人强化接种,才是目前当务之急。

美卫生专家:奥密克戎BA.2亚型占美国新病例1/4以上

据美国约翰斯·霍普金斯大学发布的全球新冠肺炎数据实时统计系统,截至美国东部时间3月20日下午6点,全美共报告新冠肺炎确诊79733159例,死亡971162例。

约翰斯·霍普金斯大学的数据显示,截至20日的过去一周,美国日均新增确诊病例3.05万例,日均新增死亡病例879例。

美国消费者新闻与商业频道报道说,美国卫生专家警告说,奥密克戎毒株的亚型变异毒株BA.2可能很快导致美国新冠确诊病例再次上升。白宫首席医疗顾问安东尼·福奇等官员表示,奥密克戎BA.2亚型的传播性比奥密克戎毒株高出约50%至60%,但目前尚无证据表明感染BA.2亚型后会导致更严重的症状。据估计,奥密克戎BA.2亚型约占目前美国新增病例的25%或30%。

奥密克戎隐匿传播,本轮疫情波及28个省份

这次席卷各地的奥密克戎变异株多为BA.2亚分支,较以往病毒株的传播性和隐匿性都更强。世卫组织根据丹麦的疫情数据进行测算,该亚变体比奥密克戎原始毒株BA.1的传染性增加了30%。新冠病毒呈现隐匿传播,全国多地的感染病例中无症状感染者数量多、占比大。

国务院联防联控机制3月19日15时召开新闻发布会通报,3月1日到18日,我国本土疫情累计报告感染者超过29000例,波及28个省份,其中吉林省1个省份累计报告超过1万例。另有4个省份累计报告超过1千例,还有10个省份累计报告在100至1000例之间。

香港新增14149例新冠肺炎确诊病例 新增死亡205例

香港特区政府卫生署卫生防护中心3月20日公布,截至当日零时,香港新增14149例新冠肺炎确诊病例,其中经核酸检测确诊病例5876例。3月19日,新冠病毒快速抗原测试阳性结果人士申报系统接获8273例呈报病例。

据香港医管局介绍,过去24小时,有205名确诊患者在公立医院离世。

上海3月20日新增本土病例“24+734”例

上海市卫健委今早(21日)通报:2022年3月20日0—24时,新增本土新冠肺炎确诊病例24例和无症状感染者734例,其中22例确诊病例和652例无症状感染者在隔离管控中发现,其余在相关风险人群排查中发现。新增境外输入性新冠肺炎确诊病例17例和无症状感染者2例,均在闭环管控中发现。

2022年3月20日0—24时,上海新增本土新冠肺炎确诊病例24例。治愈出院1例。

张文宏谈第四针疫苗接种引热议:这可能是最后一个疫情“寒冬”

张文宏谈第四针疫苗接种的问题上了热搜,这让很多用户很关心,具体的情况。

据央视新闻报道称,国家传染病医学中心主任张文宏接受采访时表示:针对包括变异体在内的研究确凿显示,新冠疫苗在降低重症和死亡率方面效果显著,尤其第三针疫苗可以使抗体水平升高几十倍。“一旦出现本土病例,可以最大程度把病人的重症化降到我们力所能及的最低水平。第四针疫苗现在还不需要那么着急,到时候可以有更多国际经验为我们所用。”

英国将为75岁以上人群接种第二剂新冠疫苗加强针

英国将为75岁以上人群接种第二剂新冠疫苗加强针

河北省新增本土新型冠状病毒肺炎确诊病例51例,无症状感染者356例

河北卫健委消息,2022年3月20日0―24时,河北省新增本土新型冠状病毒肺炎确诊病例51例(廊坊市48例、唐山市2例、沧州市1例),新增本土无症状感染者356例(廊坊市351例、唐山市3例、沧州市1例、邯郸市1例)。治愈出院17例,无症状感染者解除医学观察25例。

2021年至今4例新冠本土死亡病例,均有严重基础性疾病

3月18日,国家卫健委疫情通报了新增死亡病例2例,均为本土病例。健康时报根据国家卫健委通报数据梳理发现,从2021年1月至今,31个省区市一共报告4例死亡病例;根据各地通报,4例死亡病例均年龄偏大,且有严重的基础性疾病。

江苏省防疫专家呼吁:老年人积极接种新冠病毒疫苗

“老年人群感染新冠病毒后,发生重症和死亡的风险较高,接种新冠病毒疫苗,可大大降低感染后发生重症和死亡的风险。”汪志国建议,符合接种条件的老年人,可按照有关规定,尽快完成全程接种并接种加强针。60岁以上人群如符合序贯加强免疫接种条件,也可选择序贯加强免疫接种疫苗。

目前我国已完成32亿剂次、我省已完成近1.96亿剂次的新冠病毒疫苗接种。“总体来说新冠病毒疫苗安全性良好,有些受种者有一过性发热、红肿硬结等轻微反应,一般不需要处理。”汪志国提醒,根据我国新冠病毒疫苗接种技术指南,患有高血压、高血脂、糖尿病等慢性病的老年人,如果健康状况稳定、药物控制良好,建议接种新冠病毒疫苗。

“如之前打疫苗曾发生过敏性休克或喉头水肿等严重过敏反应,或正在发热,处于感染性疾病、神经系统疾病等急性发作期,建议不接种新冠疫苗。”汪志国表示,对自己能否接种疫苗尚不清楚,可前往接种门诊,详细咨询接种医生。

专家再次呼吁一定要加快推进老年人,特别是高龄老人接种新冠疫苗

传染病的防控就是三个原则:一是发现和管理传染源。我们搞的检测以及隔离就是为了这个。二是阻断传播途径。戴口罩、保持社交距离,包括隔离,也是为了阻断传播途径。三是保护易感人群。从这两年多来全球各个国家以及各个地区疫情防控的工作来看,我们可以看到,凡是违背常识、违反原则,我们就会承受巨大的代价,最大的代价就是生命的丧失,尤其是规模化的生命丧失。新冠病毒是一个新病毒,全人群易感,而在易感人群当中,最脆弱的就是老人。因为老人往往大多有基础疾病,同时他的免疫力比较弱,一旦发生感染,相较于成人和儿童,重症和死亡风险是非常高的。我们国家由于疫情防控得好,我们没有这方面的统计数据,我们看看全球的数据,全球截至目前,因新冠肺炎死亡的人数已经超过600万,从各个国家报道的数据来看,平均年龄都在70岁左右。按照美国CDC的统计数据,相较于18-29岁的年轻人,他的数据是经常在变动的,65-74岁人群的住院风险提高了4倍,死亡风险提高了65倍,75-84岁的人群相较于18-29岁人群住院风险提高了8倍,死亡风险增加了140倍。85岁以上的人群,住院风险增加了12倍,死亡风险提高了340倍。近期大家也看到,香港暴发了大规模的新冠疫情,大家也看到报道,接种疫苗者的死亡率是0.04%,没有接种疫苗者的死亡率是1.25%,两者相差30多倍。而在香港报道的死亡人员当中,90%以上是老人。由此可见,接种疫苗对于降低老人的重症和死亡是有效的。

如果我们要建立坚强的免疫屏障,这个短板必须补上。只有把老年人的疫苗接种率提升起来,我们才真正能够为我们国家的疫情防控赢得主动、赢得时间。所以在此我再次呼吁,一定要加快推进老年人,特别是高龄老人的接种率,因为这对个人、对家庭、对社会、对国家都好。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1967573, encodeId=c501196e5732a, content=<a href='/topic/show?id=7fe36335360' target=_blank style='color:#2F92EE;'>#死亡人数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63353, encryptionId=7fe36335360, topicName=死亡人数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Apr 01 19:26:00 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081169, encodeId=a71c20811691d, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Fri Jun 03 08:26:00 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632428, encodeId=432e1632428f4, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Tue May 24 19:26:00 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772148, encodeId=16aa1e72148c9, content=<a href='/topic/show?id=122b63381b3' target=_blank style='color:#2F92EE;'>#死亡病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63381, encryptionId=122b63381b3, topicName=死亡病例)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d938370790, createdName=xuqianhua, createdTime=Mon Jun 20 02:26:00 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204542, encodeId=ee15120454216, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>真的很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Mar 21 09:36:29 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204536, encodeId=4f9d12045364a, content=疫情早日结束, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936e6556711, createdName=ms7000000490578574, createdTime=Mon Mar 21 09:14:10 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204527, encodeId=563b120452e7b, content=疫情早日过去, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Mon Mar 21 08:43:47 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1967573, encodeId=c501196e5732a, content=<a href='/topic/show?id=7fe36335360' target=_blank style='color:#2F92EE;'>#死亡人数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63353, encryptionId=7fe36335360, topicName=死亡人数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Apr 01 19:26:00 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081169, encodeId=a71c20811691d, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Fri Jun 03 08:26:00 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632428, encodeId=432e1632428f4, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Tue May 24 19:26:00 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772148, encodeId=16aa1e72148c9, content=<a href='/topic/show?id=122b63381b3' target=_blank style='color:#2F92EE;'>#死亡病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63381, encryptionId=122b63381b3, topicName=死亡病例)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d938370790, createdName=xuqianhua, createdTime=Mon Jun 20 02:26:00 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204542, encodeId=ee15120454216, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>真的很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Mar 21 09:36:29 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204536, encodeId=4f9d12045364a, content=疫情早日结束, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936e6556711, createdName=ms7000000490578574, createdTime=Mon Mar 21 09:14:10 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204527, encodeId=563b120452e7b, content=疫情早日过去, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Mon Mar 21 08:43:47 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1967573, encodeId=c501196e5732a, content=<a href='/topic/show?id=7fe36335360' target=_blank style='color:#2F92EE;'>#死亡人数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63353, encryptionId=7fe36335360, topicName=死亡人数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Apr 01 19:26:00 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081169, encodeId=a71c20811691d, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Fri Jun 03 08:26:00 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632428, encodeId=432e1632428f4, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Tue May 24 19:26:00 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772148, encodeId=16aa1e72148c9, content=<a href='/topic/show?id=122b63381b3' target=_blank style='color:#2F92EE;'>#死亡病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63381, encryptionId=122b63381b3, topicName=死亡病例)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d938370790, createdName=xuqianhua, createdTime=Mon Jun 20 02:26:00 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204542, encodeId=ee15120454216, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>真的很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Mar 21 09:36:29 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204536, encodeId=4f9d12045364a, content=疫情早日结束, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936e6556711, createdName=ms7000000490578574, createdTime=Mon Mar 21 09:14:10 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204527, encodeId=563b120452e7b, content=疫情早日过去, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Mon Mar 21 08:43:47 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1967573, encodeId=c501196e5732a, content=<a href='/topic/show?id=7fe36335360' target=_blank style='color:#2F92EE;'>#死亡人数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63353, encryptionId=7fe36335360, topicName=死亡人数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Apr 01 19:26:00 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081169, encodeId=a71c20811691d, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Fri Jun 03 08:26:00 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632428, encodeId=432e1632428f4, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Tue May 24 19:26:00 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772148, encodeId=16aa1e72148c9, content=<a href='/topic/show?id=122b63381b3' target=_blank style='color:#2F92EE;'>#死亡病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63381, encryptionId=122b63381b3, topicName=死亡病例)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d938370790, createdName=xuqianhua, createdTime=Mon Jun 20 02:26:00 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204542, encodeId=ee15120454216, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>真的很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Mar 21 09:36:29 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204536, encodeId=4f9d12045364a, content=疫情早日结束, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936e6556711, createdName=ms7000000490578574, createdTime=Mon Mar 21 09:14:10 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204527, encodeId=563b120452e7b, content=疫情早日过去, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Mon Mar 21 08:43:47 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1967573, encodeId=c501196e5732a, content=<a href='/topic/show?id=7fe36335360' target=_blank style='color:#2F92EE;'>#死亡人数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63353, encryptionId=7fe36335360, topicName=死亡人数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Apr 01 19:26:00 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081169, encodeId=a71c20811691d, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Fri Jun 03 08:26:00 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632428, encodeId=432e1632428f4, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Tue May 24 19:26:00 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772148, encodeId=16aa1e72148c9, content=<a href='/topic/show?id=122b63381b3' target=_blank style='color:#2F92EE;'>#死亡病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63381, encryptionId=122b63381b3, topicName=死亡病例)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d938370790, createdName=xuqianhua, createdTime=Mon Jun 20 02:26:00 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204542, encodeId=ee15120454216, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>真的很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Mar 21 09:36:29 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204536, encodeId=4f9d12045364a, content=疫情早日结束, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936e6556711, createdName=ms7000000490578574, createdTime=Mon Mar 21 09:14:10 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204527, encodeId=563b120452e7b, content=疫情早日过去, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Mon Mar 21 08:43:47 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
    2022-03-21 ms3000000876072209

    #学习#真的很不错

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1967573, encodeId=c501196e5732a, content=<a href='/topic/show?id=7fe36335360' target=_blank style='color:#2F92EE;'>#死亡人数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63353, encryptionId=7fe36335360, topicName=死亡人数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Apr 01 19:26:00 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081169, encodeId=a71c20811691d, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Fri Jun 03 08:26:00 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632428, encodeId=432e1632428f4, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Tue May 24 19:26:00 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772148, encodeId=16aa1e72148c9, content=<a href='/topic/show?id=122b63381b3' target=_blank style='color:#2F92EE;'>#死亡病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63381, encryptionId=122b63381b3, topicName=死亡病例)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d938370790, createdName=xuqianhua, createdTime=Mon Jun 20 02:26:00 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204542, encodeId=ee15120454216, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>真的很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Mar 21 09:36:29 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204536, encodeId=4f9d12045364a, content=疫情早日结束, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936e6556711, createdName=ms7000000490578574, createdTime=Mon Mar 21 09:14:10 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204527, encodeId=563b120452e7b, content=疫情早日过去, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Mon Mar 21 08:43:47 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
    2022-03-21 ms7000000490578574

    疫情早日结束

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1967573, encodeId=c501196e5732a, content=<a href='/topic/show?id=7fe36335360' target=_blank style='color:#2F92EE;'>#死亡人数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63353, encryptionId=7fe36335360, topicName=死亡人数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Apr 01 19:26:00 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081169, encodeId=a71c20811691d, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Fri Jun 03 08:26:00 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632428, encodeId=432e1632428f4, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Tue May 24 19:26:00 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772148, encodeId=16aa1e72148c9, content=<a href='/topic/show?id=122b63381b3' target=_blank style='color:#2F92EE;'>#死亡病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63381, encryptionId=122b63381b3, topicName=死亡病例)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d938370790, createdName=xuqianhua, createdTime=Mon Jun 20 02:26:00 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204542, encodeId=ee15120454216, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>真的很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Mar 21 09:36:29 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204536, encodeId=4f9d12045364a, content=疫情早日结束, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936e6556711, createdName=ms7000000490578574, createdTime=Mon Mar 21 09:14:10 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204527, encodeId=563b120452e7b, content=疫情早日过去, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Mon Mar 21 08:43:47 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
    2022-03-21 ms7000002063403376

    疫情早日过去

    0

相关资讯

BMJ:免疫缺陷人群接种新冠肺炎疫苗后效果研究

免疫功能低下人群接种Covid-19疫苗后的血清转换率显著低于常人,尤其是器官移植受者。在所有患者组中,接种第二剂量与血清转化增加相关,接种第三针可实现先前无应答人群的血清转化。

ARD:秋水仙碱预防与 COVID-19 疫苗接种后痛风发作减少有关

COVID-19 疫苗接种与痛风发作的几率增加相关,痛风发作主要发生在每次疫苗接种后的第 1 个月,并且与秋水仙碱预防负相关。

BMJ:新冠肺炎变异株患者的临床差异以及疫苗效果研究

mRNA疫苗在预防与新冠肺炎变异株导致入院方面非常有效,但需要接种加强针后可实现对OmiCon变异株的有效保护。接种疫苗人群不幸感染后的临床表现显著低于未接种人群。

国家卫健委:根据我国疫苗研发进展,可能会增加更多的加强免疫接种选择

国家卫生健康委副主任曾益新18日在国新办新闻发布会上表示,近期又对新冠病毒疫苗加强免疫接种策略做了一些补充和完善,增加了序贯加强免疫。所谓的序贯加强免疫,就是加强免疫可以选择跟原来基础免疫不同的疫苗,

科普:辉瑞mRNA疫苗(复必泰)不安全吗?谣言的来龙去脉!

自从3月1日mRNA新冠疫苗BNT162b2递交FDA的评审文件被公开披露后,各种夺人眼球的“标题党”信息一时之间在国内社交媒体中疯传。

NEJM:美国北卡罗来纳州新冠肺炎疫苗接种后9个月疗效评估

BNT162b2、mRNA-1273和Ad26.COV2.S,这三款疫苗在降低Covid-19相关住院和死亡方面均具有持久的效果,但随着时间的推移,对预防感染的保护作用的减弱